Related Experiment Video
Updated: Jul 11, 2025

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Biosimilars for Rheumatoid Arthritis: Riding the 2023 Wave [Podcast]
Stanley B Cohen1, Mariah Z Leach2
1Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Abstract:
This article discusses some of the queries and concerns that patients may have about initiating or switching to treatment with a biosimilar for rheumatoid arthritis following the US 2023 release of several biosimilars of the adalimumab reference product, also known by the brand name, Humira. The article also covers the difference between a generic medicine and a biosimilar, and the clinical evidence to support the safety and efficacy of adalimumab biosimilars in patients with rheumatoid arthritis.
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
The JAK-STAT Signaling Pathway
Connective Tissue Cell Types
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
Microorganisms in Medicine and Therapeutics

